Compare CHWY & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | ALKS |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.4B |
| IPO Year | 2019 | 2012 |
| Metric | CHWY | ALKS |
|---|---|---|
| Price | $21.20 | $45.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 20 |
| Target Price | $28.64 | ★ $56.21 |
| AVG Volume (30 Days) | ★ 7.0M | 1.8M |
| Earning Date | 12-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $12,601,500,000.00 | $1,475,899,000.00 |
| Revenue This Year | $7.32 | $23.57 |
| Revenue Next Year | $6.75 | $6.58 |
| P/E Ratio | $49.71 | ★ N/A |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $17.40 | $27.00 |
| 52 Week High | $37.34 | $55.67 |
| Indicator | CHWY | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 60.42 |
| Support Level | $19.78 | $39.41 |
| Resistance Level | $22.31 | $47.40 |
| Average True Range (ATR) | 0.78 | 1.47 |
| MACD | 0.09 | 0.58 |
| Stochastic Oscillator | 56.77 | 84.53 |
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.